822
Views
49
CrossRef citations to date
0
Altmetric
Reviews

Biomedical applications of microneedles in therapeutics: recent advancements and implications in drug delivery

, , &

Bibliography

  • Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
  • Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 2012;64:1547–1568.

•• One of the most cited recent articles on microneedles delivery

  • Quinn HL, Kearney MC, Courtenay AJ, et al. The role of microneedles for drug and vaccine delivery. Expert Opin Drug Deliv. 2014;11:1769–1780.
  • Kim YC, Prausnitz MR. Enabling skin vaccination using new delivery technologies. Drug Deliv Transl Res. 2011;1:7–12.
  • Kim YC, Zehrung D, Courtney J, et al. Delivery systems for intradermal vaccination. Curr Top Microbiol Immunol. 2012;351:77–112.
  • Kang SM, Song JM, Kim YC. Novel influenza vaccinations. Exp Rev Vaccines. 2012;11:547–560.
  • Suh H, Shin J, Kim YC. Microneedle patches for vaccine delivery. Clin Exp Vaccine Res. 2014;3:42–49.
  • Hoffmann C, Buchholz L, Schnitzler P. Reduction of needlestick injuries in healthcare personnel at a university hospital using safety devices. J Occup Med Toxicol. 2013;8:20.
  • Mecklem RL, Neumann CM. Defining and managing biohazardous waste in U.S. research-oriented universities: a survey of environmental health and safety professionals. J Environ Health. 2003;66:17–22.
  • Thummel KE. First-pass drug metabolism and its impact on oral drug delivery - Preface. Adv Drug Deliv Rev. 1997;27:97–98.
  • Zhou CP, Liu YL, Wang HL, et al. Transdermal delivery of insulin using microneedle rollers in vivo. Int J Pharm. 2010;392:127–133.
  • Cormier M, Johnson B, Ameri M, et al. Transdermal delivery of desmopressin using a coated microneedle array patch system. J Control Release. 2004;97:503–511.

•• Explores macro flux technology

  • Pappinen S, Tikkinen S, Pasonen-Seppanen S, et al. Rat epidermal keratinocyte organotypic culture (ROC) compared to human cadaver skin: the effect of skin permeation enhancers. Eur J Pharm Sci. 2007;30:240–250.
  • Pearson FE, O’Mahony C, Moore AC, et al. Induction of CD8 T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine. Vaccine. 2015;33:3248–3255.
  • Tuan-Mahmood TM, McCrudden MT, Torrisi BM, et al. Microneedles for intradermal and transdermal drug delivery. Eur J Pharm Sci. 2013;50:623–637.

• This review article focuses on recent and future developments for MN technology, including the latest type of MN design

  • Ahad A, Al-Saleh AA, Akhtar N, et al. Transdermal systemic delivery of antidiabetic drugs: formulation and delivery strategies. Drug Discov Today. 2015;20:1217–1227.
  • Liu Y, Eng PF, Guy OJ, et al. Advanced deep reactive-ion etching technology for hollow microneedles for transdermal blood sampling and drug delivery. IET Nanobiotechnol. 2013;7:59–62.
  • Swain S, Beg S, Singh A, et al. Advanced techniques for penetration enhancement in transdermal drug delivery system. Curr Drug Deliv. 2011;8:456–473.

• Advanced techniques for penetration enhancement have been discussed here

•• This paper is the first published study on the use of microfabricated microneedles to enhance drug delivery across skin

  • Laurent PE, Bourhy H, Fantino M, et al. Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults. Vaccine. 2010;28:5850–5856.
  • Henry S, McAllister DV, Allen MG, et al. Microfabricated microneedles: A novel approach to transdermal drug delivery. J Pharml Sci. 1998;87:922–925.

• Microfabricated microneedles have been discussed in detail

  • Wei-Ze L, Mei-Rong H, Jian-Ping Z, et al. Super-short solid silicon microneedles for transdermal drug delivery applications. Int J Pharm. 2010;389:122–129.
  • Qiu Y, Gao Y, Hu K, et al. Enhancement of skin permeation of docetaxel: A novel approach combining microneedle and elastic liposomes. J Control Release. 2008;129:144–150.
  • Yerramreddy TR, Milewski M, Penthala NR, et al. Novel 3-O-pegylated carboxylate and 3-O-pegylated carbamate prodrugs of naltrexone for microneedle-enhanced transdermal delivery. Bioorg Med Chem Lett. 2010;20:3280–3283.
  • Banks S, Paudel K, Brogden N, et al. Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin. Pharm Res. 2011;28:1211–1219.
  • Milewski M, Yerramreddy TR, Ghosh P, et al. In vitro permeation of a pegylated naltrexone prodrug across microneedle-treated skin. J Control Release. 2010;146:37–44.
  • Milewski M, Stinchcomb A. Vehicle composition influence on the microneedle-enhanced transdermal flux of naltrexone hydrochloride. Pharm Res. 2011;28:124–134.
  • Mikolajewska P, Donnelly R, Garland M, et al. Microneedle pre-treatment of human skin improves 5-aminolevulininc acid (ALA)- and 5-aminolevulinic acid methyl ester (MAL)-induced ppix production for topical photodynamic therapy without increase in pain or erythema. Pharm Res. 2010;27:2213–2220.
  • Badran MM, Kuntsche J, Fahr A. Skin penetration enhancement by a microneedle device (Dermaroller®) in vitro: Dependency on needle size and applied formulation. Euro J Pharm Sci. 2009;36:511–523.

• Dermaroller® has been discussed in this paper

  • Yoon J, Son T, Choi E-H, et al. Enhancement of optical skin clearing efficacy using a microneedle roller. J Biomed Opt. 2008;13:021103–021103-021105.
  • Li X, Zhao R, Qin Z, et al. Microneedle pretreatment improves efficacy of cutaneous topical anesthesia. The Am J Emerg Med. 2010;28:130–134.
  • Wing D, Prausnitz MR, Buono MJ. Skin pretreatment with microneedles prior to pilocarpine iontophoresis increases sweat production. Clin Physiol Funct Imaging. 2013;33:436–440.
  • Kaur M, Ita KB, Popova IE, et al. Microneedle-assisted delivery of verapamil hydrochloride and amlodipine besylate. Euro J Pharm Biopharm. 2014;86:284–291.
  • Ramadan WH, Khreis NA, Kabbara WK. Simplicity, safety, and acceptability of insulin pen use versus the conventional vial/syringe device in patients with type 1 and type 2 diabetes mellitus in Lebanon. Patient Prefer Adherence. 2015;9:517–528.
  • Wojciechowski P, Niemczyk-Szechowska P, Olewinska E, et al. Clinical efficacy and safety of insulin aspart compared with regular human insulin in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis. Pol Arch Med Wewn. 2015;125:141–151.
  • Kelsey MM, Bjornstad P, McFann K, et al. Testosterone concentration and insulin sensitivity in young men with type 1 and type 2 diabetes. Pediatr Diabetes. 2015. DOI:10.1111/pedi.12255. Epub 17 Feb 2015.
  • Martanto W, Davis S, Holiday N, et al. Transdermal delivery of insulin using microneedles in vivo. Pharm Res. 2004;21:947–952.
  • Zhou C-P, Liu Y-L, Wang H-L, et al. Transdermal delivery of insulin using microneedle rollers in vivo. Int J Pharm. 2010;392:127–133.
  • Cormier M, Daddona PE. Macroflux technology for transdermal delivery of therapeutic proteins and vaccines. Drugs Pharm Sci. 2003;126:589–598.
  • Lin W, Cormier M, Samiee A, et al. Transdermal delivery of antisense oligonucleotides with microprojection patch (macroflux®) technology. Pharm Res. 2001;18:1789–1793.
  • Pearton M, Allender C, Brain K, et al. Gene delivery to the epidermal cells of human skin explants using microfabricated microneedles and hydrogel formulations. Pharm Res. 2008;25:407–416.
  • Han T, Das DB. Permeability enhancement for transdermal delivery of large molecule using low-frequency sonophoresis combined with microneedles. J Pharm Sci. 2013;102:3614–3622.
  • Naguib YW, Kumar A, Cui Z. The effect of microneedles on the skin permeability and antitumor activity of topical 5-fluorouracil. Acta Pharm Sin B. 2014;4:94–99.
  • Van Der Maaden K, Jiskoot W, Bouwstra J. Microneedle technologies for (trans)dermal drug and vaccine delivery. J Control Release. 2012;161:645–655.
  • Yuen C, Liu Q. Hollow agarose microneedle with silver coating for intradermal surface-enhanced Raman measurements: a skin-mimicking phantom study. J Biomed Opt. 2015;20:61102.
  • Alarcon JB, Hartley AW, Harvey NG, et al. Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines. Clin Vaccine Immunol. 2007;14:375–381.
  • Huang J, D’Souza AJ, Alarcon JB, et al. Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine. Clin Vaccine Immunol. 2009;16:719–725.
  • Morefield GL, Tammariello RF, Purcell BK, et al. An alternative approach to combination vaccines: intradermal administration of isolated components for control of anthrax, botulism, plague and staphylococcal toxic shock. J Immune Based Ther Vaccines. 2008;6:5.
  • Wendelboe AM, Grafe C, McCumber M, et al. Inducing herd immunity against seasonal influenza in long-term care facilities through employee vaccination coverage: a transmission dynamics model. Comput Math Methods Med. 2015;2015:178247.
  • Belshe RB. Current status of live attenuated influenza virus vaccine in the US. Virus Res. 2004;103:177–185.
  • Beran J, Ambrozaitis A, Laiskonis A, et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Medicine. 2009;7:13.
  • Leroux-Roels I, Vets E, Freese R, et al. Seasonal influenza vaccine delivered by intradermal microinjection: a randomised controlled safety and immunogenicity trial in adults. Vaccine. 2008;26:6614–6619.
  • Holland D, Booy R, De Looze F, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis. 2008;198:650–658.
  • Arnou R, Icardi G, De Decker M, et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine. 2009;27:7304–7312.

• Report on intradermal influenza vaccine for older adults – Multicenter phase III clinical assessment

  • Van Der Maaden K, Trietsch SJ, Kraan H, et al. Novel hollow microneedle technology for depth-controlled microinjection-mediated dermal vaccination: a study with polio vaccine in rats. Pharm Res. 2014;31:1846–1854.
  • Gupta J, Denson DD, Felner EI, et al. Rapid local anesthesia in human subjects using minimally invasive microneedles. Clin J Pain. 2012;28:129.
  • Sivamani RK, Stoeber B, Wu GC, et al. Clinical microneedle injection of methyl nicotinate: stratum corneum penetration. Skin Res Technol. 2005;11:152–156.
  • Sivamani RK, Stoeber B, Liepmann D, et al. Microneedle penetration and injection past the stratum corneum in humans. J Dermatol Treatment. 2009;20:156–159.
  • Davis SP, Martanto W, Allen MG, et al. Hollow metal microneedles for insulin delivery to diabetic rats. IEEE Trans Biomed Eng. 2005;52:909–915.

• In vivo insulin delivery using HMNs

  • McAllister DV, Wang PM, Davis SP, et al. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Pnas. 2003;100:13755–13760.
  • Gardeniers HJ, Luttge R, Berenschot EJ, et al. Silicon micromachined hollow microneedles for transdermal liquid transport. J Microelectromech Syst. 2003;12:855–862.
  • Roxhed N, Samel B, Nordquist L, et al. Painless drug delivery through microneedle-based transdermal patches featuring active infusion. IEEE Trans Biomed Eng. 2008;55:1063–1071.
  • Nordquist L, Roxhed N, Griss P, et al. Novel microneedle patches for active insulin delivery are efficient in maintaining glycaemic control: an initial comparison with subcutaneous administration. Pharm Res. 2007;24:1381–1388.
  • Lee K, Lee HC, Lee DS, et al. Drawing lithography: three‐dimensional fabrication of an ultrahigh‐aspect‐ratio microneedle. Adv Mater. 2010;22:483–486.
  • Pettis RJ, Ginsberg B, Hirsch L, et al. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. Diabetes Technol Therap. 2011;13:435–442.
  • Pettis RJ, Hirsch L, Kapitza C, et al. Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes. Diabetes Technol Therap. 2011;13:443–450.
  • Harvey A, Kaestner S, Sutter D, et al. Microneedle-based intradermal delivery enables rapid lymphatic uptake and distribution of protein drugs. Pharm Res. 2011;28:107–116.
  • Norman JJ, Brown MR, Raviele NA, et al. Faster pharmacokinetics and increased patient acceptance of intradermal insulin delivery using a single hollow microneedle in children and adolescents with type 1 diabetes. Pediatric Diabetes. 2013;14:459–465.
  • Thakur RRS, Fallows SJ, McMillan HL, et al. Microneedle-mediated intrascleral delivery of in situ forming thermoresponsive implants for sustained ocular drug delivery. J Pharm Pharmacol. 2014;66:584–595.
  • Jun H, Han M-R, Kang N-G, et al. Use of hollow microneedles for targeted delivery of phenylephrine to treat fecal incontinence. J Control Release. 2015;207:1–6.
  • Wang PM, Cornwell M, Hill J, et al. Precise microinjection into skin using hollow microneedles. J Invest Dermatol. 2006;126:1080–1087.
  • Van Der Maaden K, Sekerdag E, Schipper P, et al. Layer-by-layer assembly of inactivated poliovirus and N-trimethyl chitosan on pH-sensitive microneedles for dermal vaccination. Langmuir. 2015;31:8654−8660.
  • Van Der Maaden K, Varypataki EM, Romeijn S, et al. Ovalbumin-coated pH-sensitive microneedle arrays effectively induce ovalbumin-specific antibody and T-cell responses in mice. Eur J Pharm Biopharm. 2014;88:310–315.
  • Ma Y, Gill HS. Coating solid dispersions on microneedles via a molten dip-coating method: development and in vitro evaluation for transdermal delivery of a water-insoluble drug department of chemical engineering. J Pharm Sci. 2014;103:3621–3630.
  • Ma Y, Tao WQ, Krebs SJ, et al. Vaccine delivery to the oral cavity using coated microneedles induces systemic and mucosal immunity. Pharm Res. 2014;31:2393–2403.
  • Chris E, Naomi CD, William CW, et al. Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque. Vaccine. Forthcoming 2014. DOI:10.1016/j.vaccine.2015.01.089.
  • Quan FS, Kim YC, Vunnava A, et al. Intradermal vaccination with influenza VLPs using microneedles induces superior protection to intramuscular immunization. J Virol. 2010;84:7760–7769.
  • Kim YC, Quan FS, Compans RW, et al. Fomulation of microneedles coated with virus-like particle influenza vaccine. AAPS PharmSciTech. 2010;11:1193–1201.
  • Quan FS, Kim YC, Compans RW, et al. Dose sparing microneedles vaccination with H1 influenza VLPs. J Control Release. 2010;147:326–332.
  • Song JM, Kim YC, Barlow PG, et al. Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. Antiviral Res. 2010;88:244–247.
  • Kim YC, Quan FS, Compans RW, et al. Long-term storage and stability kinetics of influenza vaccines using coated microneedle. Pharm Res. 2011;28:135–144.
  • Kim YC, Quan FS, Yoo DG, et al. Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine. 2009;27:6932–6938.
  • Quan FS, Kim YC, Yoo DG, et al. Stabilization of influenza vaccine enhances protection by microneedle delivery in the skin. PLoS One. 2009;4:e7152.
  • Kim YC, Quan FS, Yoo DG, et al. Enhanced memory responses to H1N1 influenza vaccination in the skin using vaccine coated-microneedles. J Infect Dis. 2010;201:190–198.
  • Kim YC, Quan FS, Compans RW, et al. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release. 2010;142:187–195.
  • Koutsonanos DG, Vassilieva EV, Stavropoulou A, et al. Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep. 2012;2:357.
  • Kim NW, Lee MS, Kim KR, et al. Polyplex-releasing microneedles for enhanced cutaneous delivery of DNA vaccine. J Control Release. 2014;179:11–17.
  • Choi HJ, Bondy BJ, Yoo DG, et al. Stability of whole inactivated influenza virus vaccine during coating onto metal microneedles. J Control Release. 2013;166:159–171.
  • Kim YC, Yoo DG, Compans RW, et al. Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles. J Control Release. 2013;172:579–588.
  • Weldon WC, Zarnitsyn VG, Esser ES, et al. Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine. PLoS One. 2012;7:e41501.
  • Edens C, Collins ML, Ayers J, et al. Measles vaccination using a microneedle patch. Vaccine. 2013;31:3403–3409.
  • Kommareddy S, Baudner BC, Bonificio A, et al. Influenza subunit vaccine coated microneedle patches elicit comparable immune responses to intramuscular injection in guinea pigs. Vaccine. 2013;31:3435–3441.
  • Kim YC, Song JM, Lipatov AS, et al. Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch. Eur J Pharm Biopharm. 2012;81:239–247.
  • Song JM, Kim YC, Ej O, et al. DNA vaccination in the skin using microneedles improves protection against influenza. Mol Ther. 2012;20:1472–1480.
  • Wang BZ, Gill HS, He C, et al. Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity. J Control Release. 2014;178:1–7.
  • Koutsonanos DG, Esser ES, McMaster SR, et al. Enhanced immune responses by skin vaccination with influenza subunit vaccine in young hosts. Vaccine. Forthcoming 2015. DOI:10.1016/j.vaccine.2015.01.086.
  • Vrdoljak A, McGrath MG, Carey JB, et al. Coated microneedle arrays for transcutaneous delivery of live virus vaccines. J Control Release. 2012;159:34–42.
  • Pearson FE, McNeilly CL, Crichton ML, et al. Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice. PLoS One. 2013;8:e67888.
  • Quan FS, Kim YC, Song JM, et al. Long-term protective immunity from an influenza virus-like particle vaccine administered with a microneedle patch. Clin Vaccine Immunol. 2013;20:1433–1439.
  • Chen MC, Huang SF, Lai KY, et al. Fully embeddable chitosan microneedles as a sustained release depot for intradermal vaccination. Biomaterials. 2013;34:3077–3086.
  • Kines RC, Zarnitsyn V, Johnson TR, et al. Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles. PLoS One. 2015;10:e0120797.
  • DeMuth PC, Min Y, Huang B, et al. Polymer multilayer tattooing for enhanced DNA vaccination. Nat Mater. 2013;12:367–376.
  • DeMuth PC, Li AV, Abbink P, et al. Vaccine delivery with microneedle skin patches in nonhuman primates. Nat Biotechnol. 2013;31:1082–1085.
  • Gonzalez-Gonzalez E, Ra H, Hickerson RP, et al. siRNA silencing of keratinocyte-specific GFP expression in a transgenic mouse skin model. Gene Ther. 2009;16:963–972.
  • Chong RH, Gonzalez-Gonzalez E, Lara MF, et al. Gene silencing following siRNA delivery to skin via coated steel microneedles: in vitro and in vivo proof-ofconcept. J Control Release. 2013;166:211–219.
  • Ross S, Scoutaris N, Lamprou D, et al. Inkjet printing of insulin microneedles for transdermal delivery. Drug Deliv Transl Res. 2015;5:451–461.

• Inkjet printing of insulin microneedles for transdermal delivery has been discussed

  • Pearton M, Saller V, Coulman SA, et al. Microneedle delivery of plasmid DNA to living human skin: formulation coating, skin insertion and gene expression. J Control Release. 2012;160:561–569.
  • Zhang Y, Brown K, Siebenaler K, et al. Development of lidocaine-coated microneedle product for rapid, safe, and prolonged local analgesic action. Pharm Res. 2012;29:170–177.
  • Ma YZ, Gill HS. Coating solid dispersions on microneedles via a molten dip-coating method: development and in vitro evaluation for transdermal delivery of a water insoluble drug. J Pharm Sci. 2014;103:3621–3630.
  • Zhang Y, Siebenaler K, Brown K, et al. Adjuvants to prolong the local anesthetic effects of coated microneedle products. Int J Pharm. 2012;439:187–192.
  • Peters EE, Ameri M, Wang XM, et al. Erythropoietin-coated zp-microneedle transdermal system: preclinical formulation, stability, and delivery. Pharm Res. 2012;29:1618–1626.
  • Tas C, Mansoor S, Kalluri H, et al. Delivery of salmon calcitonin using a microneedle patch. Int J Pharm. 2012;423:257–263.
  • Khan H, Mehta P, Msallam H, et al. Smart microneedle coatings for controlled delivery and biomedical analysis. J Drug Target. 2014;22:790–795.
  • Lee KJ, Park SH, Lee JY, et al. Perivascular biodegradable microneedle cuff for reduction of neointima formation after vascular injury. J Control Release. 2014;192:174–181.
  • Ameri M, Kadkhodayan M, Nguyen J, et al. Human growth hormone delivery with a microneedle transdermal system: preclinical formulation, stability, delivery and pk of therapeutically relevant doses. Pharm. 2014;6:220–234.
  • Van Der Maaden K, Yu HX, Sliedregt K, et al. Nanolayered chemical modification of silicon surfaces with ionizable surface groups for pH-triggered protein adsorption and release: application to microneedles. J Mater Chem B. 2013;1:4466–4477.
  • Boehm RD, Daniels J, Stafslien S, et al. Polyglycolic acid microneedles modified with inkjet-deposited antifungal coatings. Biointerphases. 2015;10:011004.
  • DeMuth PC, Moon JJ, Suh H, et al. Releasable layer-by-layer assembly of stabilized lipid nanocapsules on microneedles for enhanced transcutaneous vaccine delivery. ACS Nano. 2012;6:8041–8051.
  • Donnelly RF, Singh TR, Garland MJ, et al. Hydrogel-forming microneedle arrays for enhanced transdermal drug delivery. Adv Funct Mater. 2012;22:4879–4890.
  • Wickenheiser MR, Bordeaux JS, Robinson JK. Melanoma screening by physicians: time for a policy change in the United States. JAMA Dermatol. 2014;150:1045–1046.
  • Iannacone MR, Youlden DR, Baade PD, et al. Melanoma incidence trends and survival in adolescents and young adults in Queensland, Australia. Int J Cancer. 2015;136:603–609.
  • Czarnecki D. Response to “assessment of the effect of migration on melanoma incidence trends in australia between 1982 and 2010 among people under 30”. Acta Dermato-Venereologica. 2015;95:120–120.
  • Agarwala SS. Intralesional therapy for advanced melanoma: promise and limitation. Curr Opin Oncol. 2015;27:151–156.
  • Uddin MJ, Scoutaris N, Klepetsanis P, et al. Inkjet printing of transdermal microneedles for the delivery of anticancer agents. Int J Pharm. 2015;494:593–602.
  • Gill, HS, Prausnitz MR. Coating formulations for microneedles. Pharm Res. 2007;7:1369–1380.
  • Ahmad HR, Khan H, Arshad MS, et al. Microneedle coating techniques for transdermal drug delivery. Pharmaceutics 2015;7:486–502.
  • Hirobe S, Azukizawa H, Hanafusa T, et al. Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch. Biomaterials. 2015;57:50–58.
  • Katsumi H. Development of a novel transdermal delivery system of alendronate, a nitrogen containing bisphosphonate, using a new type of hydrophilic patch and dissolving microneedle arrays. Yakugaku Zasshi-J Pharm Soc Jpn. 2014;134:427–431.
  • Lahiji SF, Dangol M, Jung H. A patchless dissolving microneedle delivery system enabling rapid and efficient transdermal drug delivery. Sci Rep. 2015;5:7914.
  • McCrudden MTC, Torrisi BM, Al-Zahrani S, et al. Laser-engineered dissolving microneedle arrays for protein delivery: potential for enhanced intradermal vaccination. J Pharm Pharmacol. 2015;67:409–425.
  • Yan L, Raphael AP, Zhu XY, et al. Nanocomposite-strengthened dissolving microneedles for improved transdermal delivery to human skin. Adv Healthcare Mater. 2014;3:555–564.
  • Ono I, Akasaka Y, Takada K. Administration of basic fibroblast growth factor (bfgf) through self-dissolving microneedles for local therapy of skin. Wound Repair Regen. 2013;21:A37–A37.
  • Kim M, Yang H, Kim H, et al. Novel cosmetic patches for wrinkle improvement: retinyl retinoate- and ascorbic acid-loaded dissolving microneedles. Int J Cosmetic Sci. 2014;36:207–212.
  • Ito Y, Ohta J, Imada K, et al. Dissolving microneedles to obtain rapid local anesthetic effect of lidocaine at skin tissue. J Drug Target. 2013;21:770–775.
  • Loizidou EZ, Williams NA, Barrow DA, et al. Structural characterisation and transdermal delivery studies on sugar microneedles: experimental and finite element modelling analyses. Eur J Pharm Biopharm. 2015;89:224–231.
  • Garland MJ, Caffarel-Salvador E, Migalska K, et al. Dissolving polymeric microneedle arrays for electrically assisted transdermal drug delivery. J Control Release. 2012;159:52–59.
  • Sullivan SP, Koutsonanos DG, Del Pilar Martin M, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med. 2010;16:915–920.

•• This paper recently published about dissolving microneedle patches that can provide a new technology for simpler and safer vaccination with improved immunogenicity that could facilitate increased vaccination coverage

  • Matsuo K, Yokota Y, Zhai Y, et al. A low-invasive and effective transcutaneous immunization system using a novel dissolving microneedle array for soluble and particulate antigens (vol 161, pg 10, 2012). J Control Release. 2014;184:9–9.
  • Matsuo K, Hirobe S, Yokota Y, et al. Transcutaneous immunization using a dissolving microneedle array protects against tetanus, diphtheria, malaria, and influenza (vol 160, pg 495, 2012). J Control Release. 2014;184:18–19.
  • Kommareddy S, Baudner BC, Oh S, et al. Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens. J Pharm Sci. 2012;101:1021–1027.
  • Edens C, Collins ML, Goodson JL, et al. A microneedle patch containing measles vaccine is immunogenic in non-human primates. Vaccine. Forthcoming 2015. DOI:10.1016/j.vaccine.2015.02.074.
  • Vassilieva EV, Kalluri H, McAllister D, et al. Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature. Drug Deliv Transl Res. 2015;5:360–371.
  • Matsuo K, Yokota Y, Zhai Y, et al. A low-invasive and effective transcutaneous immunization system using a novel dissolving microneedle array for soluble and particulate antigens. J Control Release. 2012;161:10–17.
  • Liu S, Jin MN, Quan YS, et al. The development and characteristics of novel microneedle arrays fabricated from hyaluronic acid, and their application in the transdermal delivery of insulin. J Control Release. 2012;161:933–941.
  • Ke CJ, Lin YJ, Hu YC, et al. Multidrug release based on microneedle arrays filled with pH-responsive PLGA hollow microspheres. Biomaterials. 2012;33:5156–5165.
  • Chen MC, Wang KW, Chen DH, et al. Remotely triggered release of small molecules from LaB6@SiO2-loaded polycaprolactone microneedles. Acta Biomaterialia. 2015;13:344–353.
  • Walsh L, Ryu J, Bock S, et al. Nanotopography facilitates in vivo transdermal delivery of high molecular weight therapeutics through an integrin-dependent mechanism. ACS Nano. 2014;15:2434−2441.

•• Influence of nanotopography on transdermal delivery has been discussed in detail with molecular mechanism

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.